FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 755 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Updated Oncogene-Addicted mNSCLC Living Guideline v1.3 February 26, 2026 3 Questions Cancer Caregivers Can Ask Themselves to Help Prevent Burnout July 29, 2021 Learning the lessons of COVID-19: Protecting cancer services and research through... November 9, 2020 FDA Approves Lutetium Lu 177 Dotatate for Paediatric Patients 12 Years... May 15, 2024 Load more HOT NEWS Cancer Clinical Trials Bounce Back After Significant COVID-19 Disruption: Data From... Preclinical Study May Have Found New Treatment Option for Triple-Negative Breast... It’s a fair COP: Why our chief clinician went to a... Newly Developed RSClin Provides Prognostic Information in HR-positive, HER2-negative Early Breast...
